"This makes public trust in these services essential," it added. In another blow to the company, seven of 23andMe’s ...

Back in September, all of 23andMe's independent directors also resigned from its board — a rare move that followed drawn-out ...

It has since faced several business issues and saw its stock price drop below $1. Wojcicki attempted to take 23andMe private, ...

Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...

No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

But her efforts to do so had disappointed 23andMe’s independent directors, all seven of whom resigned in September. They ...

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...

Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...

Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...

In September, independent directors of the Board of 23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, ...

23andMe, a popular South San Francisco-based genetic testing company, is laying off 40% of its workers after struggling with ...